About: Marketing in Heterozygous Advantage

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Marketing in Heterozygous Advantage Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Marketing in Heterozygous Advantage
Creator	Hagtvedt, Jones Todd, Gregory
Source	PMC
abstract	As the rapidly advancing possibilities of biotechnology have outstripped the adaptive capacity of current legal and ethical institutions, a vigorous debate has arisen that considers the boundaries of appropriate use of this technology, particularly when applied to humans. This article examines ethical concerns surrounding the development of markets in a particular form of human genetic engineering in which heterozygotes are fitter than both homozygotes, a condition known as heterozygous advantage. To begin, we present a generalized model of the condition, illuminated by the application to sickle-cell anemia. Next, we propose a typology of related markets, some of which are currently functioning with available products and services, and others that are widely viewed as imminent. We suggest the manner in which perverse incentives may arise for firms that market genetic intervention in circumstances where heterozygous advantage is possible. Finally, we propose that this misalignment of incentives with social welfare has arisen from both ill-conceived market intervention where markets are capable of achieving efficient outcomes and the lack of market intervention where markets have failed. We offer specific legal and regulatory approaches for reform.
has issue date	2007-02-15(xsd:dateTime)
bibo:doi	10.1007/s10551-006-9301-4
has license	no-cc
sha1sum (hex)	a74c29bfc488ed46a2bd41117889f82a3af8b426
schema:url	https://doi.org/10.1007/s10551-006-9301-4
resource representing a document's title	Marketing in Heterozygous Advantage
has PubMed Central identifier	PMC7087662
schema:publication	J Bus Ethics
resource representing a document's body	covid:a74c29bfc488ed46a2bd41117889f82a3af8b426#body_text
is schema:about of	named entity 'markets' named entity 'condition' named entity 'markets' named entity 'ethical' named entity 'Heterozygous' named entity 'MARKETING' named entity 'HETEROZYGOTES' named entity 'CONCERNS' named entity 'EFFICIENT' named entity 'PARTICULAR' named entity 'MODEL OF' named entity 'GENERALIZED' named entity 'APPLICATION' named entity 'INSTITUTIONS' named entity 'FAILED' named entity 'ADVANTAGE' named entity 'FIRMS' named entity 'ILLUMINATED' named entity 'INTERVENTION' named entity 'APPROPRIATE' named entity 'CURRENTLY' named entity 'HETEROZYGOUS' named entity 'IMMINENT' named entity 'PRODUCTS' named entity 'HETEROZYGOUS' named entity 'ADVANTAGE' named entity 'REGULATORY' named entity 'VIGOROUS' named entity 'SICKLE-CELL ANEMIA' named entity 'SURROUNDING' named entity 'CURRENT' named entity 'USE OF' named entity 'OUTCOMES' named entity 'CAPABLE' named entity 'WHERE' named entity 'SPECIFIC' named entity 'HUMAN GENETIC' named entity 'ILL' named entity 'CONDITION' named entity 'APPLIED' named entity 'GENETIC INTERVENTION' named entity 'HAVE' named entity 'MISALIGNMENT' named entity 'BEGIN' named entity 'SUGGEST' named entity 'PRESENT' named entity 'OFFER' named entity 'KNOWN' named entity 'DEVELOPMENT' named entity 'FITTER' named entity 'INCENTIVES' named entity 'MARKETS' named entity 'TECHNOLOGY' named entity 'LEGAL' named entity 'ETHICAL' named entity 'MARKET' named entity 'HOMOZYGOTES' named entity 'FUNCTIONING' named entity 'HUMANS' named entity 'ADVANCING' named entity 'RELATED' named entity 'BIOTECHNOLOGY' named entity 'TYPOLOGY' named entity 'DEBATE' named entity 'APPROACHES' named entity 'AVAILABLE' named entity 'FORM' named entity 'CONCEIVED' named entity 'LACK' named entity 'ARTICLE' named entity 'ADAPTIVE CAPACITY' named entity 'RAPIDLY' named entity 'SERVICES' named entity 'POSSIBLE' named entity 'GENETIC ENGINEERING' named entity 'BOUNDARIES' named entity 'SOCIAL WELFARE' named entity 'rapidly' named entity 'efficient' named entity 'heterozygous advantage' named entity 'gene' named entity 'malaria'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software